We have published a research article on the generation and characterization of iPS cell lines with fluorescent protein with ISL1 expression. Tsukamoto S, Nakade K, Wakabayashi T, Nakashima K, Takami M, Hemmi Y, Kuramochi Y, Shimizu T, Arai Y, Matsuo-Takasaki M, Noguchi M, Nakamura Y, Miwa Y, Hayashi Y. Generation of two ISL1-tdTomato reporter human induced pluripotent stem cell lines using CRISPR-Cas9 genome editing. Stem Cell Res. 2021 May;53:102363. doi: 10.1016/j.scr.2021.102363. Epub 2021 Apr 22. PMID: 34087992. I’d like to thank all the co-authors.Congratulations, Tsukamoto-san! We’re aiming to use these iPS cells to develop cellular assays to monitor ISL1 expression.
We have published a research article on the generation and characterization of iPS cells from adrenoleukodystrophy patients. Kuramochi Y, Awaya T, Matsuo-Takasaki M, Takami M, An Y, Li J, Hemmi Y, Wakabayashi T, Arai Y, Inoue J, Noguchi M, Nakamura Y, Asaka I, Akimoto K, Saito MK, Hayashi Y. Generation of two human induced pluripotent stem cell lines derived from two X-linked adrenoleukodystrophy patients with ABCD1 mutations. Stem Cell Res. 2021 May;53:102337. doi: 10.1016/j.scr.2021.102337. Epub 2021 Apr PMID: 33901816. I’d like to thank all the co-authors.Congratulations, Kuramochi-kun! We’re aiming to use these iPS cells to develop disease models and new therapies of adrenoleukodystrophy!
We have published a review article about “Studying Abnormal Chromosomal Diseases Using Patient-Derived Induced Pluripotent Stem Cells” in Frontiers in Cellular Neuroscience. Hayashi Y, Takami M, Matsuo-Takasaki M. Studying Abnormal Chromosomal Diseases Using Patient-Derived Induced Pluripotent Stem Cells. Front Cell Neurosci. 2020;14:224. Published 2020 Aug 13. doi:10.3389/fncel.2020.00224
We have published a research article on the generation and characterization of iPS cells from patient cells of genetic kidney disease. Arai Y, Takami M, An Y, Matsuo-Takasaki M, Hemmi Y, Wakabayashi T, Inoue J, Noguchi M, Nakamura Y, Sugimoto K, Takemura T, Okita K, Osafune K, Takasato M, Hayata T, Hayashi Y.Generation of two human induced pluripotent stem cell lines derived from two juvenile nephronophthisis patients with NPHP1 deletion.Stem Cell Res. 2020 May;45:101815. doi: 10.1016/j.scr.2020.101815. Epub 2020 Apr 21. PMID: 32361464 I’d like to thank all the co-authors.Congratulations, Arai-kun! We’re aiming to use these iPS cells to develop disease models and new therapies of nephronophthisis !
RIKEN’s International Program Associate (IPA) is a non-Japanese doctoral candidate attending a Japanese or overseas graduate school participating in RIKEN’s joint graduate school program. IPAs conduct research at RIKEN under the supervision of RIKEN scientists as part of work toward obtaining a PhD. RIKEN’s joint graduate school program is based on agreements with a number of Japanese and overseas universities and aims to identify and foster talented young scientists capable of contributing to the advancement of science for the global community.https://www.riken.jp/en/careers/programs/ipa/index.html Now, we’re recruiting IPA during this October to next March.The deadline is April 30. If you’re eligible and interested in our lab,please let me know by an email.
By the end of March, we had 4 lab members left our lab. One undergraduate trainee goes on to public graduate school in Tokyo.Two master program trainees join a Japanese big cosmetic company and an international pharmaceutical company.One technical staff joins our collaborative startup company in Tokyo. I really congratulate them and wish for their future success.
Now, RIKEN is calling for applications for the position of Special Postdoctoral Researcher (SPDR) for FY 2021.https://www.riken.jp/en/careers/programs/spdr/career2021/index.html Also, we can employ one junior postdoc (within around 5 years after getting PhD) in my laboratory now. Please let me know if you’re interested to study using human iPS cells in Tsukuba, Japan!
A new co-authored article has been published in Cell Reports.This study reveals the molecular mechanisms of retroviral silencing associated with pluripotency and reprogramming and is mainly done by Gene regulation Lab in University of Tsukuba (my former lab).Congratulations, Phuon Linh, Nishimura-sensei, and Hisatake-sensei! Bui PL, Nishimura K, Seminario Mondejar G, Kumar A, Aizawa S, Murano K, Nagata K, Hayashi Y, Fukuda A, Onuma Y, Ito Y, Nakanishi M, Hisatake K. Template Activating Factor-I α Regulates Retroviral Silencing during Reprogramming. Cell Rep. 2019 Nov 12;29(7):1909-1922.e5. doi: 10.1016/j.celrep.2019.10.010. PubMed PMID: 31722206.